Literature DB >> 28513879

The Therapeutic Potential of PI3K/Akt/mTOR Inhibitors in Breast Cancer: Rational and Progress.

Afsane Bahrami1,2, Majid Khazaei3, Soodabeh Shahidsales4, Seyed Mahdi Hassanian5,6, Malihe Hasanzadeh7, Mina Maftouh5, Gordon A Ferns8, Amir Avan5.   

Abstract

Breast cancer (BC) is the most commonly diagnosed cancer in women. The PI3K/AKT/mTOR pathway is among the most frequently dysregulated pathways in patients with BC. The activation of this pathway is associated with increased cell growth and clinical outcome, and its overexpression is associated with a poor prognosis. It has been proposed that it may be of importance as a potential therapeutic target in the treatment of BC. The aim of current review is to provide an overview of the potential utility of PI3K/Akt/mTOR inhibitors in patients with BC, with particular emphasis on recent preclinical and clinical studies. J. Cell. Biochem. 119: 213-222, 2018.
© 2017 Wiley Periodicals, Inc. © 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  BREAST CANCER; EVEROLIMUS; PI3K/Akt/mTOR INHIBITORS

Mesh：

Substances：

Year:  2017        PMID： 28513879     DOI： 10.1002/jcb.26136

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN： 0730-2312            Impact factor:   4.429


  26 in total

1.  Lysophosphatidic Acid Receptor 6 (LPAR6) Expression and Prospective Signaling Pathway Analysis in Breast Cancer.

Authors:  Kai Tao; Shipeng Guo; Rui Chen; Chengcheng Yang; Lei Jian; Haochen Yu; Shengchun Liu
Journal:  Mol Diagn Ther       Date:  2019-02       Impact factor: 4.074

2.  STEAP2 is down-regulated in breast cancer tissue and suppresses PI3K/AKT signaling and breast cancer cell invasion in vitro and in vivo.

Authors:  Qing Yang; Guoxin Ji; Jiyu Li
Journal:  Cancer Biol Ther       Date:  2019-11-07       Impact factor: 4.742

Review 3.  Understanding the role of integrins in breast cancer invasion, metastasis, angiogenesis, and drug resistance.

Authors:  Hassan Yousefi; Mousa Vatanmakanian; Mojdeh Mahdiannasser; Ladan Mashouri; Nikhilesh V Alahari; Mohammad Rafiee Monjezi; Shahrzad Ilbeigi; Suresh K Alahari
Journal:  Oncogene       Date:  2021-01-08       Impact factor: 9.867

Review 4.  PI3K/mTOR Inhibitors in the Treatment of Luminal Breast Cancer. Why, When and to Whom?

Authors:  Francesco Schettini; Giuseppe Buono; Meghana V Trivedi; Sabino De Placido; Grazia Arpino; Mario Giuliano
Journal:  Breast Care (Basel)       Date:  2017-10-19       Impact factor: 2.860

Review 5.  Myricetin-induced apoptosis in triple-negative breast cancer cells through inhibition of the PI3K/Akt/mTOR pathway.

Authors:  Preeti Sharma; Mohammad Ahmed Khan; Abul Kalam Najmi; Shubhra Chaturvedi; Mohd Akhtar
Journal:  Med Oncol       Date:  2022-10-08       Impact factor: 3.738

Review 6.  PI3K Inhibitors in Advanced Breast Cancer: The Past, The Present, New Challenges and Future Perspectives.

Authors:  Paola Fuso; Margherita Muratore; Tatiana D'Angelo; Ida Paris; Luisa Carbognin; Giordana Tiberi; Francesco Pavese; Simona Duranti; Armando Orlandi; Giampaolo Tortora; Giovanni Scambia; Alessandra Fabi
Journal:  Cancers (Basel)       Date:  2022-04-26       Impact factor: 6.575

Review 7.  PI3K Inhibitors in Breast Cancer Therapy.

Authors:  Haley Ellis; Cynthia X Ma
Journal:  Curr Oncol Rep       Date:  2019-12-11       Impact factor: 5.075

8.  The prognostic value of PI3K mutational status in breast cancer: A meta-analysis.

Authors:  Navid Sobhani; Giandomenico Roviello; Silvia P Corona; Maurizio Scaltriti; Anna Ianza; Marina Bortul; Fabrizio Zanconati; Daniele Generali
Journal:  J Cell Biochem       Date:  2018-03-01       Impact factor: 4.429

9.  p66Shc regulates podocyte autophagy in high glucose environment through the Notch-PTEN-PI3K/Akt/mTOR pathway.

Authors:  Danna Zheng; Mei Tao; Xudong Liang; Yiwen Li; Juan Jin; Qiang He
Journal:  Histol Histopathol       Date:  2019-10-25       Impact factor: 2.303

10.  Everolimus Inhibits the Progression of Ductal Carcinoma In Situ to Invasive Breast Cancer Via Downregulation of MMP9 Expression.

Authors:  Guang Chen; Xiao-Fei Ding; Kyle Pressley; Hakim Bouamar; Bingzhi Wang; Guixi Zheng; Larry E Broome; Alia Nazarullah; Andrew J Brenner; Virginia Kaklamani; Ismail Jatoi; Lu-Zhe Sun
Journal:  Clin Cancer Res       Date:  2019-12-23       Impact factor: 12.531
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.